DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (2026)

Alopecia | Current Treatment | Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)

Alopecia | Current Treatment | Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by targeting of anagen hair follicles by the host immune system resulting in varying degrees of hair loss. Topical corticosteroids and topical contact allergens are commonly prescribed to treat AA; however, AA treatment guidelines are sparse, as is clinical evidence supporting the efficacy of current therapeutic options. As the AA pipeline fills in (e.g., Pfizer’s PF-6700841, Incyte’s Jakafi), this content will offer insights from real-world claims data into prescribing trends in AA to help new players seeking to better understand current treatment practices in AA and define the market niche for their emerging product.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AA patients?
  • How have finasteride, minoxidil, and corticosteroids been integrated into the treatment algorithm, and what is their source of business? Do JAK inhibitors (e.g., Incyte’s Jakafi, Eli Lilly’s Olumiant) see off-label use in AA?
  • What percentage of AA patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of AA patients are treated with monotherapy vs. combination therapy? What are the most commonly used drug combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


  • Geographies: United States
  • Real-World Data: Longitudinal patient-level claims data analysis
  • Key Drugs Covered: Minoxidil, anthralin, finasteride, Xeljanz, Jakafi, Olumiant, clobetasol propionate, Elidel
  • Key Analysis Provided: brand/therapy usage across longitudinal patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, product-level patient flow charts


  • Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
    • Treatment Algorithms Claims Data Analysis Alopecia US March 2019

Already a Client? Log in to access this report.

  • Pub Date: March 2019
  • Author(s): Ian Love, PhD
  • Ian is an analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, specializing in niche and rare diseases. Ian conducts primary and secondary research to gauge the market landscapes of these diseases, thoroughly analyzing disease etiology, current treatments, unmet need, and emerging therapies expected to impact their respective markets. He received his doctorate in biomedical sciences from the University of Massachusetts Medical School and his in cell & molecular biology from the Worcester Polytechnic Institute. Prior to joining Decision Resources Group, Dr. Love was an Instructor in the Department of Internal Medicine at Virginia Commonwealth University.

Purchase Report

Recent reports:
You may also be interested in: